A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs
← catalyst calendarNCT07336446 · readout in 891 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
300estimated
Sites
18
Countries
Australia, Canada, China +5
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-01-27 | actual | When the study began enrolling |
| Primary completion | 2029-01-26 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-01-26 | estimated | The whole study's end, after follow-up |
| First posted | 2026-01-13 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Prostate Cancer
Interventions
- Drug: AZD9750
- Drug: AZD5305 — also filed as Saruparib
Primary outcomes
what the primary-completion date above is the date OFNumber of participants with dose-limiting toxicity (DLT), as defined in the protocol (Part A only)
measured From first dose of study intervention to 28 days post first dose
Number of participants with Adverse Events and Serious Adverse Events
measured From first dose of study intervention up to 37 days after the last dose of study treatment
Number of participants with Adverse Events leading to discontinuation of study intervention
measured From first dose of study intervention up to 37 days after the last dose of study treatment
Clinically significant changes from baseline in vital signs.
measured From first study dose up to 37 days after the last dose of study treatment
Clinically significant changes from baseline in physical examination.
measured From first dose of study intervention up to 37 days after the last dose of study treatment
Clinically significant changes from baseline in ECOG PS.
measured From first dose of study intervention up to 37 days after the last dose of study treatment
Clinically significant changes from baseline in ECGs.
measured From first dose of study intervention up to 37 days after the last dose of study treatment
Clinically significant changes from baseline in laboratory parameters.
measured From first dose of study intervention up to 37 days after the last dose of study treatment
Proportion of participants achieving a ≥50% decrease in PSA from baseline (PSA50) (Part B only)
measured From first dose of study intervention up to 14 days after the last dose of study treatment
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed